Drug Trial Radar · NCT02120924
A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
Last checked: Nov 19, 2026Latest source record: Jun 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,009
Actual
Start
Jul 2013
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Actavis Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.
Conditions
- Rosacea
Interventions
Azelaic acidDrug
Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
VehicleDrug
Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
FinaceaDrug
Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts.Time frame: Baseline to Week 12
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Site 24
Fremont, California
Site 22
Santa Monica, California
Site 1
Brandon, Florida
Site 3
Fort Myers, Florida
Site 27
Jacksonville, Florida
Site 19
Miami, Florida
Site 9
Miami, Florida
Site 29
Miramar, Florida
Site 2
Tampa, Florida
Site 15
Chicago, Illinois
Site 4
Plainfield, Indiana
Site 14
Lake Charles, Louisiana
Site 17
Glenn Dale, Maryland
Site 6
Bay City, Michigan
Site 30
Clinton Township, Michigan
Site 16
Las Vegas, Nevada
Site 11
Raleigh, North Carolina
Site 23
Winston-Salem, North Carolina
Site 26
Philadelphia, Pennsylvania
Site 12
Warwick, Rhode Island
Site 28
Simpsonville, South Carolina
Site 20
Nashville, Tennessee
Site 21
College Station, Texas
Site 5
Dallas, Texas
Site 8
El Paso, Texas
Site 13
Houston, Texas
Site 7
Katy, Texas
Site 18
Salt Lake City, Utah
Site 10
Norfolk, Virginia
Site 25
University Place, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.